Erland Hvittfeldt
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [18F]PSMA-1007 PET/CT: a comparison to MRI using histopathology as reference.
Journal: EJNMMI reports
Published: October 18, 2024
PET/CT imaging 2 h after injection of [18F]PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h.
Journal: European journal of hybrid imaging
Published: February 27, 2023
Freely Available, Fully Automated AI-Based Analysis of Primary Tumour and Metastases of Prostate Cancer in Whole-Body [18F]-PSMA-1007 PET-CT.
Journal: Diagnostics (Basel, Switzerland)
Published: August 01, 2022
Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients.
Journal: EJNMMI research
Published: May 18, 2022
Biokinetics and dosimetry of 18 F-PSMA-1007 in patients with prostate cancer.
Journal: Clinical physiology and functional imaging
Published: April 19, 2022
Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 13, 2021
Triple dosing with high doses of buprenorphine: Withdrawal and plasma concentrations.
Journal: Journal of opioid management
Published: August 28, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026